Navigation Links
Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
Date:12/7/2011

GREENWOOD VILLAGE, Colo., Dec. 7, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.  The patent also includes claims for these compositions that target clinical treatments for inflammation and inflammatory diseases and conditions, such as arthritis and allergies.

Dr. David Bar-Or, Ampio's Chief Scientific Officer, noted "This is an important, composition of matter patent that complements the already extensive and robust portfolio of worldwide issued patents for Ampion™. The mechanism of action of Ampion™, an innate human biological small molecular weight compound, is unique as it not only inhibits the early activation of memory T cells but also affects an upstream event in inflammation by tightening vascular permeability among other effects."

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer further noted " We believe that multiple inflammatory conditions might benefit from this biological drug and the company is currently testing two such indications in clinical trials:

  • The Ampion™-In-Knee (AIK) clinical trial for the treatment of osteoarthritis of the knee being conducted in Australia.  This trial was recently expanded to include a direct comparison to steroids and vehicle control and is expected to conclude by the end of this year.
  • The IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado for the treatment of rhinitis.  This tria
    '/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
2. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
3. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
4. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
5. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
6. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
7. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
8. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
9. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
10. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
11. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... 3 GIFT-I study of its investigational, all-oral, interferon ... with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of the ... Japan . 1 GIFT-I evaluated genotype ... Japanese patients, with and without cirrhosis, who were ...
(Date:5/26/2015)... Calif. , May 26, 2015 Thoratec ... mechanical circulatory support therapies to save, support and restore ... Goldman Sachs 36 th Annual Healthcare Conference on ... , President and Chief Executive Officer, will provide an ... Daylight time (5:00 p.m., Eastern Daylight Time). ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: ... from the Phase 3 OPTiM study in the ... The data published in JCO , which ... American Society of Clinical Oncology (ASCO) in 2013 and ... in patients with unresected stage IIIB, IIIC or IV ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
(Date:5/27/2015)... (PRWEB) May 27, 2015 SIMpalm ... helped its client to launch an Android version for ... merchants to accept credit, debit and ACH payments on ... Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . The iOS version ... has been recently updated by SIMpalm. , Forte ...
(Date:5/27/2015)... Get Tested Coachella Valley , a ... of HIV, will recognize its most influential, passionate and ... Ambassador Awards, to be held on Twitter on June ... first for public health campaigns, the online awards ceremony ... influencers for breaking down stigma, spreading awareness and educating ...
(Date:5/27/2015)... According to research conducted by Dr. Huay-Zong ... Dallas some migraine patients have an increased likelihood of ... apparently also have some shared risk factors -- particularly ... a history of diabetes and/or smoking. Both conditions were ... in particular was less common in Hispanics. , ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces ... business to better serve the needs of couples in Chicagoland. ... on the Northwest side of the city at 4920 North ... by calling the Chicago office at (773) 794–1818. This ... of Chicago. The other 2 offices are in Gurnee ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
Breaking Medicine News(10 mins):Health News:Forte Payment System Launches Android Version of Payment App 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 2Health News:Regional Public Health Campaign to Host 1st Annual YesGTCV Social Ambassador Awards 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 2Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 3Health News:Santa Rosa Orthopaedics Offers Insights into Recent Study Results Connecting Migraines with Chronic Conditions Such as Carpal Tunnel Syndrome 4Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2
... , THURSDAY, Sept. 29 (HealthDay News) -- One-quarter of American ... to new research from the U.S. Agency for Healthcare Research ... blood pressure, also known as hypertension, 29 percent were black ... federal agency noted in its Sept. 27 News and ...
... , THURSDAY, Sept. 29 (HealthDay News) -- Campus-wide smoking bans ... habit, new research suggests. The finding stems from a ... a ban and one without. "Although we haven,t pinpointed ... most to the positive changes in students, smoking rates, having ...
... DCThrough the identification of a gene,s impact on a ... continue to make progress in understanding the mechanics ... of white matter, known as myelination. The study, published ... of The Journal of Neuroscience , identified Sox17 ...
... might think, cancer and diabetes appear to have some biology in ... the Cell Press journal, Cell, a pathway that initially ... also influences the odds that mice develop or resist diabetes. ... Lin28b become more sensitive to insulin and less prone to diabetes ...
... , HOUSTON, Sept. 29, 2011 Hormone researchers at ... on providing long-term treatment options for diabetes, obesity and ... naturally occurring estrogen. They now believe that ... body functions in both females and males. While estradiol ...
... 28, 2011 - (BRONX, NY) - People taking oral steroids ... severe vitamin D deficiency, according to a study of more ... Albert Einstein College of Medicine of Yeshiva University. Their ... of Clinical Endocrinology and Metabolism, suggest that physicians should more ...
Cached Medicine News:Health News:1 in 4 U.S. Adults Treated for High Blood Pressure: Report 2Health News:Campus Smoking Bans May Help College Students Quit 2Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Diabetes and cancer: A shared biological basis 2Health News:UH researchers explain hormonal role in glucose and fat metabolism 2Health News:Oral steroids linked to severe vitamin D deficiency in nationwide study 2
... This comfortable pre-fabricated orthosis is designed ... distal third humeral diaphyseal fractures. The ... circumferential soft tissue compression for optimal ... full range-of-motion of both the shoulder ...
Provides secure fracture immobilization while allowing for full range of motion at shoulder and elbow...
... This night splint features a ... 10 degrees dorsiflexion, designed to provide ... symptoms of plantar fasciitis or Achilles ... the need to order left or ...
... This economically priced semi-rigid post op shoe ... soft cotton-poly blend breathable upper will keep ... hook and loop closure provides even tension ... additional comfort and support for your patient. ...
Medicine Products: